News | November 27, 2025
Valneva shifts French ops to Lyon
Valneva will consolidate its French operations at its Lyon site and close its Nantes location
Valneva will consolidate its French operations at its Lyon site and close its Nantes location
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
These findings follow positive Phase 3 results presented earlier this year
Merck will showcase results in innovative solutions in HIV treatment and prevention
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Subscribe To Our Newsletter & Stay Updated
